Level Bio

Level Bio's mission is to build a Nordic life science conglomerate by commercializing innovative diagnostic solutions through an integrated business model. A key strategic achievement was the 2026 divestiture of its development subsidiary, CyberGene, to Devyser, which has refocused the company on its core distribution and service strengths via Techtum Lab. The current strategy leverages Techtum's established Nordic network to act as a de-risked commercialization partner for diagnostic innovators, positioning the company for growth through potential new asset acquisitions and expanded service offerings.

An integrated commercial and operational platform providing end-to-end distribution, regulatory, technical, and commercialization services for diagnostic products in the Nordic market.

Competes with global giants (e.g., Thermo Fisher) and regional distributors in the Nordic diagnostics service sector. Its advantage is deep regional expertise and customer intimacy as a full-service partner, but faces constant margin pressure and competition from direct sales forces of large diagnostic companies.